BioXcel Therapeutics, Inc. (BTAI) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 27, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for BioXcel Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, BioXcel Therapeutics, Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Continuing Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does BioXcel Therapeutics, Inc. actually do?
Answer:
BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence (AI) to develop transformative medicines, primarily in neuroscience. Its lead neuroscience candidate, BXCL501 (marketed as IGALMI), is an orally dissolving sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar disorders in adults, and is being developed for agitation in Alzheimer's dementia. The company's immuno-oncology asset, BXCL701, an oral innate immune activator, is being deprioritized. BioXcel Therapeutics utilizes a proprietary AI platform to potentially reduce drug development costs and accelerate timelines by identifying new therapeutic indications for existing drugs.
Question:
What are BioXcel Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by sales of IGALMI, its approved product for the acute treatment of agitation. The company is also seeking potential commercial partners for IGALMI and its other pipeline candidates.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required